MENU
Advanced Materials Intelligence
  1. Home
  2. AstraZeneca Company Profile | Drug Discovery & DDS

AstraZeneca Company Profile | Drug Discovery & DDS

Back to Technology, Institution & Company Guides

Company Profile

AstraZeneca
— A multimodality pharmaceutical company that brought ADCs, radiopharmaceuticals, cell therapy, and nucleic acids together through partnerships and acquisitions

AstraZeneca is a drug discovery and DDS specialty.Have almost everything in your pipeline.A few pharmaceutical companies. An antibody drug complex (ADC) has partnered with the first three cooperatives, its products, and radioactive drugs acquired Diasion in 2024, cell therapy acquired Gracell and EsoBiotec, and Nucleic acid drugs obtained in partnership with Ionis. Total sales for FY2025US$587 millionResearch and development costs$143,200 millionComment In this article, the entire company is concise,Where to invest in manufacturing, which modality is obtained from anyoneFilter by

Composition: AstraZeneca PLC submitted to SEC in the U.S. Form 20-F (submitted on February 24, 2026), Form 6-K (submitted on July 27, 2026), Form 6-K (submitted on July 27, 2026), Form 6-K for acquisition, approval, and investment, and ClinicalTrials.gov as primary information / final update September 2026

In this article
  1. Astrageneca in 30 seconds and standing position in drug discovery and DDS
  2. About logo and company name
  3. Where is this company in the world of drug discovery and DDS?
  4. Size of the company (the entire company is concise)
  5. Drug discovery and DDS resources
  6. Past Initiatives
  7. Future plans
  8. What is DDS?
  9. Collaboration mapping of drug discovery and DDS
  10. Technologies, Products and Services
  11. The risk of this company
  12. Glossary/Source/Ins ment and Source Response Table

1. Astrageneca in 30 seconds and standing position in drug discovery and DDS

NameAstraZeneca PLCUK Public Corporation
HeadquartersCambridge, UKCambridge Biomedical Campus
ListingLSE／STO／NYSE: AZNSubmitted 20-F (annual report of foreign companies) to US SEC
Categories in this fieldPharmaceutical Company
(Multimodality)From low・s to antibodies to cell therapy and nucleic acid
Total sales for FY2025US$587 millionPrevious year: US$5,673 million
R&D expenses$143,200 millionDecember 2025 Approx. 24% of sales
ADC Pillar
DatrowayJoint development and joint sales with Dai-ichi Sankyo
2030 goalsTotal sales: $800 billion50% of the company’s goals
1 point to press

Businesses related to drug discovery and DDS are largeBiotech and Contract Development Manufacturing (CDMO/CRO)3 types. AstraZenecaPharmaceutical CompanyHowever, features areMake new modalities and go aheadSpeed FactsHome ADC (TOP1i ADC) with Topoisomerase I in。tors, radioconjugates using actinium, CAR-T and TCR-T cell therapy, T-cell enhancer, siRNA, ligand-binding antis。, AAV gene therapy. Most of these include: ADC, Fusion, Gracell, EsoBiotec, and Ionis.External technology ownerWe are coming from partnerships and acquisitions.

How to read this article

This article explains the company's technical strategy and business.Not medical adviceHome There is no intention to recommend the use of certain drugs or compare the effects of other drugs. The results of clinical trials are based on the comparison of the numbers published by the company and at the time of evaluation. Please contact your doctor for the treatment.

2. Logo and company name

AstraZeneca。 In this article, we do not reproduce the generated image, Images obtained from the official websiteHome img/astrazeneca_logo.png Contact Us

Note: The company name on legal disclosure is AstraZeneca PLCIn Japanese, it is written as "Astragenica". AstraZeneca Co., Ltd. Rare disease business acquired in 2021Alexion(Alexa) is operated by the brand, and the number starting with ALXN will appear in the 20-F development list.

Official Site:https://www.astrazeneca.com/

3. Where is this company in the world of drug discovery and DDS?

3 types of companies involved in drug discovery and DDS In the same "pharmacy company", it is completely different where the drug is made Pharmaceutical Company Drug discovery biotech Research and development From search to approval and sales Create candidates with new modalities and methods Contract development and manufacturing of other drugs Eli Lilly／Novo Nordisk Pfizer Alnylam／Arvinas Moderna/Insilico Lonza／Samsung Biologics AppTec Secondary clinical and sales network funding Specific technical base depth Mass production capability for equipment and regulation Sales can be reduced rapidly due to the lack of patents Rely on partnering with funds for late development Disco・ation of customer development and impact of policy AstraZeneca is on the left side of this pharmaceutical company that has acquired two types of technology in partnership and acquisition. ADC is one of the leading three-complex, radiopharmaceuticals, radiopharmaceuticals, cell therapy is Gracell and EsoBiotec, nucleic acid is obtained from Ionis.
Figure 1　3 types of companies involved in drug discovery and DDS, and the position of AstraZeneca. The classification is based on this article, and the company name is an example from the company handled by this series. The calculation of this paperHome In addition to low-。, antibody and double-specific antibody, modalities are used for ADC, radioactive drugs, cell therapy (CAR-T, TCR-T, in vivo, which changes cells in the body), antis。, siRNA, and AAV gene therapy. The acquisition source of technology is based on notes on the acquisition of 20-F and the tie-up release with each company.

This is why many of the modalities arranged in the technical commentary of this series "Distribution modalities" are going to be listed in the development list of one company. However, it is separate that “being” and “Everything is made in-house”, and in this article, it distinguishes from where the modalities are obtained.

4. Scope of the company (the entire company is concise)

Indicators (million dollars)FY2023FY2024FY2025First half of 2026
Total Revenue45,81154,07358,73930,672
R&D expenses10,93513,58314,2327,545
Operating income8,19310,00313,7437,410
Acquisition of tangible fixed assets (cash flow)1,3611,9242,810―
Employee (monthly average, continuous business)86,400 people92,900 people95,100 people―
Contact Us

The above numbersCompany OverviewAstraZeneca is a research and development costNot disclosing separate breakdowns of modalities Undetermined / FutureHome 2025 employees are 10,600 in the UK, 26,900 in Europe other than the UK, 25,200 in the south, 32,400 in Oceania, Asia and Africa. The number of researchers, cell therapy and radioactive drugs, etc. are not written. Capital investments in the first half of 2026 (intangible fixed assets and software-related intangible assets) are $1.5 billion, and the company explains the reason for the increase as "investment of multiple large-scale manufacturing projects" Facts。

5. Drug discovery and DDS resources

Resource Types
People (Research Centers and Personnel)April average 95,100 (2025). Cambridge, UK In the U.S., we plan to expand our R&D base in Geysburg, Maryland and the new R&D center in Cambridge, Massachusetts.Non-dis sure of the number of researchers and employees of modalitiesFacts
Gold (R&D expenses)FY2025 $143,200 million(Approx. 24.2% of total sales). $75 billion in the first half of 2026. Non-dissemination of modalities breakdown.Facts
Gold (Manufacturing Equipment, USA)2030 in USA$500 billion(July 2025) The core is the new original drug factory in Virginia.Low・s, Peptides, Oligonucleotidesto manufacture. OthersNext-generation cell therapy facility(including Rockville, Maryland, Tarzana, California). November 2025 in Maryland$20 billionInvesting in Frédéric’s biopharmaceu plant has almost doubled its commercial capacity and presents a clinical trial drug manufacturing facility in GesarsburgFacts
Gold (Manufacturing, Research, China)In China By 2030$150 billionPlan to invest in manufacturing and R&D (January 2026).Cell Therapy and Radioactive DrugsExplanation to strengthen the ability ofFacts
Gracell(CAR-T, completed in February 2024, worth $135 million),Fusion Pharmaceuticals(Actinium-based radioactive drugs, completed in June 2024, $21 million),EsoBiotec(Wrench virus base that changes immune cells in the body, up to $2025, $10 billion)Facts
License-in partnership1st Trico (ADC 2 items), Ionis (anti-epilontersen), Eccogene (oral low-molecular GLP-1 receptor agonist, 2023), CSPC (low-molecular search using AI = 8 programs of obesity and diabetes, including contract technology, 2025/AI peptide search and monthly dosing technology), Dizal (oral EGFR inhibitor, Zegvy, 2026).Facts
University/Research Organization/Public FundJoint research with universities on drug discovery and DDS and acceptance of public funds are not specified in the 20-F・6-K confirmed in this articleNot confirmed
What did you buy in the acquisition - read from the 20-F accounting process

The 20-F Notebook describes how the acquired contents were evaluated on account. FactsHome Fusion’s Intangible Assets for Prostate CancerFPI-2265 $84bn、AZD2068is assigned The company was acquired and explained that it obtained the ability of R&D, manufacturing, and supply chain of radioactive drugs. EsoBiotec is almost everything in value.ENaBL Platform ($44 million)It was processed as "acquiring assets" rather than corporate bonds as a single asset. EsoBiotecI bought the technical foundation itselfContact Us On the other hand, the FPI-2059 from Fusion has been deducted by the “Judgement of Portfolio Priority” in 2024, and not all candidates purchased will remain.

6. Past Initiatives

TimeHome
March 2019Global Alliance between Dai-ichi Trio and Enharts (Trussuzumab Delxekan)(Up to $69 billion for the first three)Fold profits and expenses except Japan. Manufacturing and supply of ADC
July 2020Global Partnership between Dai-ichi Sankyo and Datoroway (Dart Potamab Derxekan) (up to $60 billion)The second ADC partnership with Dai-ichi Sankyo
July 2021Completed acquisition of AlexionBusiness foundation for rare diseases. siRNA/AAV gene therapy of ALXN number is also available in the development list of 20-F
December 2021Co-development and sales agreement between Ionis and eplontersenAiming for the liver with nucleic acid drugs targeting.
November 2023Eccogene introduces Oral GLP-1 receptor agonist ECC5004Aiming for obesity and metabolic diseases with low-molecular weight drugs without injection.
December 2023U.S. FDA approved FDAinua (eplontersen) (Polyneuropathic ATTR amyloidosis)First approval as a nucleic acid drug. Self-injection
February 2024Completed acquisition of GracellAZD0120 of CAR-T and FasTCAR manufacturing base to reduce production time
June 2024Completed acquisition of Fusion PharmaceuticalsThe development, manufacture, and supply network of radioactive drugs targeting.
March 2025 - MayAcquisition of EsoBiotecCompletedTo in vivo cell therapy that alters T cells in the body with vein injections without processing cells outside the body
June 2025Research collaboration in low-molecular drug discovery using CSPC and AI.Utilize AI drug discovery at a research base in China
July 2025US$5 billion investment planHome Low s, Peptides and Oligonucleotides in VirginiaThe largest single- investment and description of the company
November 2025US$20 billion in MarylandAlmost double the capacity of Frederic’s biopharmaceu plant (planned to operate in 2029)
December 2025Enharts + Perzumab in the U.S. Approved for primary treatment of HER2-positive metastatic milk cancerTo the first treatment line of metastatic cancer
January 2026$1.5 billion investment plan in China. 8th Partnership with CSPC and Obesity and DiabetesEnhanced cell therapy and radioactive pharmaceutical capabilities in China
May 2026Datroway approved for primary treatment of triple negative milk cancer in the United States. Enharts approves HER2-positive early milk cancer with two indicationsADC adaptation spreads to early and primary treatment
July 2026Achieved a part of the major evaluation items in the third phase CLARITY-Gastric01 of our own ADC sonesitatug vedotin (CLDN 18.2)and announcements. In the same month, we introduced Zeg vy worldwide rights from DizalThe company positioned as “Result of the first pivotal test as a fully owned ADC portfolio”

Main Clinical Trials (Results published by the Company)

Test (NCT number)PhaseMain evaluation itemsResults published by the Company (at the time of comparison and evaluation)
DESTINY-Breast09（NCT04784715）Phase 3 Primary treatment of HER2-positive metastatic lactose cancer (enhatsu + pertzumab)Unexpensive survival period (PFS, blind-independent centralization)Reduces the risk of disease progression or death by 44% compared to THP therapy, and PFS median is more than 3 years (THP is about 2 years). 2025 ASCO Analysis
TROPION-Breast02（NCT05374512）Phase 3 Primary treatment of immunotherapy and static metastatic triple negative milk cancer (Dattroway)PFS, full survival (OS)OS Central 5.05.0 months improvement compared to chemotherapy (Hazard ratio 0.79, 95% confidence interval 0.64 to 0.90.9, reducing the risk of disease progression or death 43% (Hazard ratio 0.57). 2025 ESMO analysis
CLARITY-Gastric01（NCT06346392）Phase 3 CLDN18.2 Secondary treatment of positive progressive gastric cancer, etc. (sonesitatug vedotin)OS and overall PFS after 3rd treatmentA statistically significant improvement in OS after 3rd treatment compared to the treatment of doctor selection. The overall PFS tends to improve, but it does not reach a significant difference.Numbers unpublished as of July 2026(Presen) schedule and company description)
NEURO-TTRansform（NCT04136184）Phase 3 Hereditary ATTR Amyloidosis Polyneuropathy (epilontersen)Serum TTR concentration, mNIS+735 analysis of 35 weeks demonstrated improvement of key evaluation items and became the basis for U.S. approval
CARDIO-TTRansform（NCT04136171）Phase 3 ATTR Amyloidosis Cardio) (eplontersen)Cardio death and cardio eventsNo major evaluation items(Announced in the first half of FY2014)

7. Future plans

2030 sales target$100 billionExpect 50% of them in the US. Company Goals
U.S. investment$500 billion
(2030))Manufacturing and R&D including manufacturing facilities for cell therapy
Investment in China$150 billion
(2030))Enhanced cell therapy and radioactive drugs
New FactoryLow・s and peptides
OrigonucleotideVirginia. Original drugs such as oral GLP-1

"Became the first global pharmaceutical company with consistent research, development and manufacturing of cell therapy" Name AbelZeta, CSPC, Harbour BioMed, Jacobio, Syneron Bio as above FactsHome In the United States, the new plant in Virginia is used for the original drug of "weight loss and metabolic disease portfolio (oral GLP-1, baxdrostat, oral PCSK9, etc.)".

Not confirmed

Both of the following are not listed in the primary material that has been confirmed in this article Undetermined / Future。

$5 billionPrices by Modality(Virginian new plant is listed as “billions of dollars” only)/Production capacity/CLARITY-Gastric01Specific numbers/ in vivo cell therapy (ENaBL)Target disease and clinical stage/With university and public institutionsDrug DevelopmentHome We do not use estimates for survey companies such as "AstraZeneca's ADC market share ○%".

8. What is this company aiming for drug discovery and DDS?

This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.

ReadPrimary Information
ADCIn addition to partner products with Dai-ichi Sankyo, we want to grow our own ADC.TOP1i ADC (STEAP2, CLDN18.2, CD22, B7-H4) and MMAE ADC (CLDN18.2, GPRC5D) are listed in the development list of 20-F. sone-ve's results are expressed as "Result of the first pivotal test as a fully owned ADC portfolio"
In cell therapyDirections to reduce “making process”bet onGracell’s FasTCAR base, EsoBiotec, has been acquired as an in vivo base, “a few weeks of process in vein injection”
Nucleic acid and peptidesIncorporating original medicine manufacturingIt is clearly stated that the new plant in Virginia produces low s, peptides and oligonucleotides. Largest single facility investment in the past
As a source of new modalitiesFocus on ChinaAcquisition of Gracell (Business in China and the United States), partnership with CSPC and Dizal to strengthen cell therapy and radioactive drugs with a $150 billion investment in ChinaFacts
Radioactive DrugsManufacture and supply20-F is the significance of Fusion’s acquisition of “Actility in R&D, Manufacturing, and Supply Chain”Facts
Only one basis for guessing

Enharts is a partnership with the first three cooperatives, with AstraZeneca’s revenue of 1,1 million dollars in the first half of 2026.Millions of millions of dollars(Receiving from sales recorded by Dai-ichi Sankyo) FactsHome ADC manufacture and supply is a contract that is responsible for the first three coexistence. In other words, Enharts is a big pillar for AstraZeneca,No more than half of the profitProducts In July 2026, I wrote “wholly owned” by the company. ADCRevenue source that does not rely on affiliationThis article reads when it is important to have Undetermined / FutureHome However, the company does not clarify whether the ADC manufacturing system is in-house, and this is the interpretation of this article.

9. Collaboration mapping of drug discovery and DDS

Partnering with DDS, a drug discovery centered on AstraZeneca Only relationships described in the SEC submission document (20-F・6-K). No media-based relationships Co-development and introduction (real line, dark blue) Production and supply of the other party Acquisition AstraZeneca Pharmaceutical Company ADC 2 items jointly developed and sold Manufacturing and supply are carried by Dai-ichi Sankyo Ionis Antis ( inua) Joint development and sales contract in 2021 CSPC (China) 8 items of AI drug discovery and obesity Eccogene・Dizal Introduction of oral low s Fusion (2024) Akthium Radioactive Drugs Gracell(2024) CAR-T and short-term manufacturing base EsoBiotec (2025) In vivo cell therapy base Acquisition of AstraZeneca (EsoBiotec)
Figure 2　Collaboration between drug discovery and DDS centered on AstraZeneca. Source: Form 20-F (Gracell・sionsion・EsoBiotec), Form 6-K (Ionis December 2021, Eccogene November 2023, CSPC June 2025, January 2026, July 2026), first three co-branded releases (March 2019, July 2020).The first three colonial line is orange because it is a contract that the first three colonials are responsible for the manufacture and supply of ADCWe are also involved in joint development and joint sales. In partnership with CSPC, there are two programs: low-。 search (2025) using AI and 8 programs (2026) of obesity and diabetes, including peptide search and monthly dose technology using AI.

10. Technologies, Products and Services

HomeMain items (20-F・6-K)Contact Us
ADC（TOP1i）Enharts (HER2), Datroway (TROP2)Approved. products with Dai-ichi Sankyo. AstraZeneca's product revenue for the first half of 2026 was $17,900 million in Enharts and $9,800 million in Datroway
ADCsonesitatug vedotin（CLDN18.2、MMAE）、puxitatug samrotecan（B7-H4、TOP1i）、AZD0516（STEAP2）、AZD4360（CLDN18.2）、AZD4512（CD22）、AZD0305（GPRC5D、MMAE）3rd phase of the development (sone-ve). Other stages are 20-F.
Radioactive DrugsFPI-2265(PSMA), AZD2068(EGFR/cMET), AZD2284(STEAP2). Both actiniumUnder development Acquisition of Fusion
Cell TherapyAZD0120(BCMA/CD19 CAR-T) AZD0754(STEAP2 CAR-T), AZD0240(KRAS G12D TCR-T), ENaBL PlatformUnder development Acquisition of Gracell and EsoBiotec
Nucleic acidWainua (eplontersen, ligand-bound antis)), ALXN2030 (siRNA targeting complementary C3), AZD6912 (siRNA)Wainua has been approved (Partnership with Ionis), and others are under development
TherapyALXN2350Contact Us
Oral hypo s and peptidesOral GLP-1 receptor agonist (from Eccogene), CSPC-derived monthly injection programContact Us
Perspective of material ians: "Efficient materials and processes" are completely different for each modality

Radioactive DrugsFrom the inside of the drugContact UsContact Us radioisotopes such as Akthium 225 are produced over time, It is necessary to secure the isotopes, combine with a chelate agent that fixes metal to antibodies and low doses, and time management to reach the patient. This is why 20-F clearly indicates the capability of manufacturing and supply chain as well as development products as the significance of Fusion acquisition. FactsHome The ability of radioactive drugs is strengthened by investing in China, but the preparation for the same issue and this article will be read. Undetermined / Future。

Nucleic acidThe hepatocyte is described as an antis of ligand binding type and aiming for the liver. FactsHome The type of ligand is not written in the release confirmed in this article, but the chemical modification and binding technology that delivers nucleic acid to specific organs is the core of DDS. New factory in VirginiaPeptides and OligonucleotidesThe plan to make the original drug means that the demand for materials such as solid-phase resins, protective groups, solvents, and chromatography resins for refining can grow significantly within the company. Undetermined / Future。

Cell TherapyIn vivo method (EsoBiotec), which converts the cells in the body by injecting the virus vector into venous cells from the conventional method of processing cells taken from the patient. If this is practical, the specific gravity of the medium, bag, and closure system for cell culture decreases,Manufacture and purification of wrench virus vectorThe specific gravity rises. Please refer to the technical commentary "Virus vector" and "CAR-T cells".

11. Risks that this company has

Risks
Patents and Price PolicyEarnings for the first half of 2026 are reported in the United States of Farxiga and decreasing China's centralized purchasing (VBP)Facts
ADC PillarsEnharts and Datroway are affiliated with Dai-ichi Sankyo. 2033-2035Facts
The possibility that the purchased technology is not growingFusion-derived FPI-2059 was reduced in 2024. In 2025, the decommissioning of the product was $210 million.Facts
Failure to expand adaptation of nucleic acid drugsClinical trials for CARDIO-TTR did not achieve major evaluation items in the Wainua heart disease.Facts
Recovery of large-scale capital investmentThe US$5 billion and US$1.5 billion investment plan assumes the goal of $8 billion in 2030. Goal is the company's and undeterminedUndetermined / Future
HomeWe partner with large investments in both the United States and China, and we can at the same time accept the impact of policy changes in both countries.

12. Glossary

ADC
A drug that combines strong drugs through a linker to antibodies. TOP1i is a topoisomerase I in。tor, MMAE is a microtube in。tor payload.
Radioconjugate
A drug that binds radioisotopes to cancer cells and emits radiation near them.
Axy 225
Radioisotope emitting alpha line. It is said that the distance of the fly is short and it acts strongly on nearby cells.
CAR-T
Cell therapy that incorporates receptors (CAR) to identify signs of cancer in patients’ T cells.
in vivo cell therapy
A method of altering immune cells in the body by administering vectors without removing cells from the body.
Antis
A short nucleic acid drug that binds to target RNA to reduce protein production.
siRNA
Nucleic acid drugs that reduce protein production by decom、 target mRNA with short RNA of two chains.
Alliance revenue
The amount received based on the contract from the sales recorded by the partner.
Conceptual diagram: A research building of modalities that differ from ADC, radioactive medicine, cell therapy, and nucleic acid is arranged in one pharmaceutical company.Concept diagram of AI generation
Figure 3　Concept diagram of the multimodality strategy of AstraZeneca (a concept diagram by AI generation). We do not copy actual facilities or products.

13. Source

  1. AstraZeneca PLC　Form 20-F for the) year ended December 31, 2025 Total sales, R&D expenses, operating income, capital investment, employees, acquisition of Gracell, Fusion, EsoBiotec, accounting processing, loss, product list, patent expiration date. https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm
  2. AstraZeneca PLC　Form 6-K “H1 and Q2 2026 results” Results of total sales, R&D costs, product revenue and capital investment in the first half of 2026, and clinical trials. https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm
  3. AstraZeneca PLC　Form 6-K “AstraZeneca plans to invest $50bn in the US” (July 22, 2025). https://www.sec.gov/Archives/edgar/data/901832/000165495425008260/a9509r.htm
  4. AstraZeneca PLC　Form 6-K “AstraZeneca manufacturing investment in Maryland” (November 24, 2025). https://www.sec.gov/Archives/edgar/data/901832/000165495425013401/a6308i.htm
  5. AstraZeneca PLC　Form 6-K "AstraZeneca invests $15bn in China through 2030" (January 29, 2026). https://www.sec.gov/Archives/edgar/data/901832/000165495426000688/a9169q.htm
  6. AstraZeneca PLC　Form 6-K "AstraZeneca enters into collaboration with CSPC" (June 13, 2025). https://www.sec.gov/Archives/edgar/data/901832/000165495425006914/a6592m.htm
  7. AstraZeneca PLC　Form 6-K "AstraZeneca agrees obesity and T2D deal with CSPC" (January 30, 2026). https://www.sec.gov/Archives/edgar/data/901832/000165495426000730/a0031r.htm
  8. AstraZeneca PLC　Form 6-K "AstraZeneca licenses novel EGFR in)tor" (July 14, 2026). https://www.sec.gov/Archives/edgar/data/901832/000165495426006637/a2449m.htm
  9. AstraZeneca PLC　Form 6-K “AstraZeneca to acquire EsoBiotec” (March 17, 2025). https://www.sec.gov/Archives/edgar/data/901832/000165495425002837/a9028a.htm
  10. AstraZeneca PLC　Form 6-K “AstraZeneca acquires Gracell” (December 27, 2023). https://www.sec.gov/Archives/edgar/data/901832/000165495423015982/a8499x.htm
  11. AstraZeneca PLC　Form 6-K "AstraZeneca, Ionis to collaborate on eplontersen" (December 7, 2021). https://www.sec.gov/Archives/edgar/data/901832/000165495421012879/a8026u.htm
  12. AstraZeneca PLC　Form 6-K “FDAinua (eplontersen) granted first US FDA approval” (December 22, 2023). https://www.sec.gov/Archives/edgar/data/901832/000165495423015901/a7568x.htm
  13. AstraZeneca PLC　Form 6-K "Agreement with Eccogene for clinical stage GLP-1RA" (November 9, 2023). https://www.sec.gov/Archives/edgar/data/901832/000165495423013971/a8748s.htm
  14. AstraZeneca PLC　Form 6-K "Datroway approved in US for 1L triple-negative BC" (May 26, 2026). https://www.sec.gov/Archives/edgar/data/901832/000165495426005309/a6573f.htm
  15. AstraZeneca PLC　Form 6-K “Enhertu approved in US for 1L HER2+ metastatic BC” (December 16, 2025). https://www.sec.gov/Archives/edgar/data/901832/000165495425013970/a6719l.htm
  16. AstraZeneca PLC　Form 6-K “Sone-Ve improved survival in gastric cancers” (July 27, 2026). https://www.sec.gov/Archives/edgar/data/901832/000165495426006895/a9459n.htm
  17. 　Press Release “Announcement of Global Development and Sales Alliance with AstraZeneca on Trussuzumab Derxekan (DS-8201)” (March 29, 2019) https://www.daiichisankyo.co.jp/media/press_release/detail/index_5623.html
  18. 　Press Release Announcement of Global Development and Sales Alliance with AstraZeneca on DS-1062 (July 27, 2020) https://www.daiichisankyo.co.jp/media/press_release/detail/index_5545.html
  19. ClinicalTrials.gov　DESTINY-Breast09（NCT04784715）。 https://clinicaltrials.gov/study/NCT04784715
  20. ClinicalTrials.gov　TROPION-Breast02（NCT05374512）。 https://clinicaltrials.gov/study/NCT05374512
  21. ClinicalTrials.gov　CLARITY-Gastric01（NCT06346392）。 https://clinicaltrials.gov/study/NCT06346392
  22. ClinicalTrials.gov　NEURO-TTRansform（NCT04136184）。 https://clinicaltrials.gov/study/NCT04136184
  23. ClinicalTrials.gov　CARDIO-TTRansform（NCT04136171）。 https://clinicaltrials.gov/study/NCT04136171
  24. AstraZeneca PLC　Official website (name and logo) https://www.astrazeneca.com/

14. Response table of claims and sources

Content
Acquisition of total sales, R&D expenses, operating income and tangible fixed assets (FY2023 to FY2025), April average and regional breakdownFactsSource 1 https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm
Approx. 24.2% of total salesThe calculation of this paperThe number of source 1 is divided by this article
Total sales, R&D costs, operating income and capital investments in the first half of 2026, the impact of the company’s revenue and alliance revenues, Farxiga and VBP in ChinaFactsSource 2 https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm
Gracell・sionsion's acquisition date and confrontation value, the breakdown of Fusion's intangible assets, EsoBiotec's ENaBL assets $44 millionFactsSource 1 https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm
Reduced FPI-2059 (2024, $14, $23, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $20, $FactsSource 1 https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm
Development list of modalities (TOP1i ADC, MMAE ADC, radioactive drugs, CAR-T, TCR-T, siRNA, antisense, AAV gene therapy) and each item name, and patent expiration years.FactsSource 1 https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm
US$5 billion investment plan, Virginia’s new plant (low- dose, peptide, oligonucleotide), cell therapy manufacturing facility, and sales of $8 billion in 2030.FactsSource 3 https://www.sec.gov/Archives/edgar/data/901832/000165495425008260/a9509r.htm
$20 billion manufacturing investment in Maryland and expected to operate in 2029FactsSource 4 https://www.sec.gov/Archives/edgar/data/901832/000165495425013401/a6308i.htm
US$1.5 billion investment plan, strengthening cell therapy and radioactive drugs, five Chinese partnersFactsSource 5 https://www.sec.gov/Archives/edgar/data/901832/000165495426000688/a9169q.htm
AI drug discovery partnership with CSPCFactsSource 6 https://www.sec.gov/Archives/edgar/data/901832/000165495425006914/a6592m.htm
Agreement with CSPC for 8 programs of obesity and diabetesFactsSource 7 https://www.sec.gov/Archives/edgar/data/901832/000165495426000730/a0031r.htm
Dizal introduced worldwide rights for Zegvys.FactsSource 8 https://www.sec.gov/Archives/edgar/data/901832/000165495426006637/a2449m.htm
Acquisition of EsoBiotec (up to $10 billion, ENaBL, altered T cells in the body with venous injection)FactsSource 9 https://www.sec.gov/Archives/edgar/data/901832/000165495425002837/a9028a.htm
AstraZeneca acquired Gracell (manufacturing time with FasTCAR).FactsSource10 https://www.sec.gov/Archives/edgar/data/901832/000165495423015982/a8499x.htm
Eplontersen contract with Ionis (re-gabapentin-bound antis), aiming for the liver)FactsSource11 https://www.sec.gov/Archives/edgar/data/901832/000165495421012879/a8026u.htm
35 weeks interim analysis of Wainua’s US approval (December 2023) and NE)-TTRansformFactsSource12 https://www.sec.gov/Archives/edgar/data/901832/000165495423015901/a7568x.htm
Introduction of Oral GLP-1 receptor agonist from EccogeneFactsReference13 https://www.sec.gov/Archives/edgar/data/901832/000165495423013971/a8748s.htm
U.S. Approval and TROPION-Breast02 Results for Triple Negative Dairy Cancer Primary Treatment in DatrowayFactsReference14 https://www.sec.gov/Archives/edgar/data/901832/000165495426005309/a6573f.htm
US approval and DESTINY-Breast09 results of Enharts + PerzumabFactsSource15 https://www.sec.gov/Archives/edgar/data/901832/000165495425013970/a6719l.htm
sone-ve's CLARITY-Gastric01 results and expression of "Result of the first pivotal trial as a fully owned ADC portfolio"FactsSource16 https://www.sec.gov/Archives/edgar/data/901832/000165495426006895/a9459n.htm
Terms of tie-up with Dai-ichi Three Co., Ltd. (up to $69 billion, $60 billion, halves of profits and costs, manufacturing and supply are the first three cooperatives)FactsSource 17/18 https://www.daiichisankyo.co.jp/media/press_release/detail/index_5623.html
NCT number, phase, and key evaluation items for each testFactsSource 19-23 https://clinicaltrials.gov/study/NCT06346392
CARDIO-TTRansform did not achieve key evaluation itemsFactsSource 2・23 https://clinicaltrials.gov/study/NCT04136171
Specific figures of CLARITY-Gastric01, modalities of investment plan, subject diseases of in vivo cell therapy, joint research with universitiesUndetermined / FutureNot listed in the source 1-16. This article does not estimate https://www.sec.gov/Archives/edgar/data/901832/000165495426006895/a9459n.htm
Target of $800 billion in total sales in 2030Undetermined / FutureSource 3. Not a company's and track record https://www.sec.gov/Archives/edgar/data/901832/000165495425008260/a9509r.htm
Drug discovery and DDS classification (pharmaceu company / drug discovery biotech / contract development manufacturing and research)The calculation of this paperThis article. Company name is an example of a company handled by this series.
Read on to grow our own ADC in addition to partner products with Dai-ichi SankyoInterpre of this article from the development list and the announcement of soone-ve
Reading of betting in a direction that reduces "creation" in cell therapyExplanation of this article from Gracell EsoBiotec acquisition
Prospects that demand for solid-phase materials can be increased by reading the original drug manufacturing of nucleic acids and peptides in-houseInterpre of this paper from Virginia's new plant
Risks that can simultaneously receive the impact of policy changes across the U.S.Interpreting this paper from investment and partnership in the United States and China

Last Updated:September 26, 2026/Troy Technical
All the figures in this article are based on the legal disclosure document (20-F・6-K) submitted by AstraZeneca PLC to the US Securities and Exchange Commission (SEC), the press release of the first three co, and the ClinicalTrials.gov。 information. We do not use estimates and media-based numbers of survey companies. The "、ulation" section is an interpretation that the article reads from the primary information and is not an announcement of the company. This article is not medical advice.

🌐 Japanese